Crossmark

Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir

Crossref DOI link: https://doi.org/10.1186/s12981-019-0230-6

Published Online: 2019-07-27

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Campogiani, Laura

Cerva, Carlotta

Maffongelli, Gaetano

Teti, Elisabetta

Pupo, Livio

Vaccarini, Sara

Cantonetti, Maria

Pennica, Alfredo

Andreoni, Massimo

Sarmati, Loredana http://orcid.org/0000-0003-1452-0333
License Information

Text and Data Mining valid from 2019-07-27

Version of Record valid from 2019-07-27
More Information

Article History

Received: 16 March 2019

Accepted: 17 July 2019

First Online: 27 July 2019

Ethics approval and consent to participate

: Not applicable.

: Signed.

: Pennica Alfredo—Participation in conferences organized by MSD and Gilead. Massimo Andreoni has received speaker fees, travel grants, and consulting fees from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, ViiV Healthcare, and Janssen-Cilag. Loredana Sarmati has received travel grants from Gilead Sciences and Merck Sharp & Dohme, payment for lectures from Gilead Sciences, Merck Sharp & Dohme and Abbvie. The other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below